Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience
Aim: Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy are recommended as the first-line treatment for hormone receptor-positive, HER2-negative metastatic breast cancer without visceral crisis. However, CDK4/6 inhibitor efficacy has been reported to differ between HER2-low and HER2-zero tumor...